Matches in Wikidata for { <http://www.wikidata.org/entity/Q102215800> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q102215800 description "2020 ވަނަ އަހަރުގެ ނޮވެމްބަރުމަހުގެ 20ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q102215800 description "artículu científicu espublizáu en payares de 2020" @default.
- Q102215800 description "scientific article published on 20 November 2020" @default.
- Q102215800 description "наукова стаття, опублікована 20 листопада 2020" @default.
- Q102215800 name "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 name "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 type Item @default.
- Q102215800 label "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 label "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 prefLabel "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 prefLabel "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 P1433 Q102215800-59A659A9-F394-48DD-89BD-D22F2136080B @default.
- Q102215800 P1476 Q102215800-9E37B9D6-B535-47B3-A15C-C3D7BC5EF3A5 @default.
- Q102215800 P2093 Q102215800-2D24ACDF-9446-4C5E-8748-A493AF818EE7 @default.
- Q102215800 P2093 Q102215800-403D9460-82AF-475E-B4CC-4AE6D0080743 @default.
- Q102215800 P2093 Q102215800-88A18084-088B-427C-9881-B6F61CE47DE0 @default.
- Q102215800 P2093 Q102215800-A2445C66-53BF-45D4-9DB4-313757451B01 @default.
- Q102215800 P2093 Q102215800-AABEBDEB-7AC4-4E70-8517-2198AAF79E4E @default.
- Q102215800 P2093 Q102215800-B24CCAC6-6F52-4F40-8629-DF16B2751684 @default.
- Q102215800 P2093 Q102215800-EE318E65-043A-48AF-97F2-DC43DEDD48F2 @default.
- Q102215800 P31 Q102215800-F4CEFB2E-AFFC-474B-8A24-B9365DF16BFA @default.
- Q102215800 P356 Q102215800-7558118F-174F-4F72-965A-8957411A849D @default.
- Q102215800 P50 Q102215800-12B6ECDE-F2FD-47A9-B1AB-4677BE863248 @default.
- Q102215800 P577 Q102215800-06ADB617-6EBA-46D3-92AA-C14FD5AF0C64 @default.
- Q102215800 P698 Q102215800-79129294-DF90-4DE0-8716-B6F586939CD5 @default.
- Q102215800 P921 Q102215800-0D60B1E6-F394-4CFB-B683-72AB9194A081 @default.
- Q102215800 P921 Q102215800-A05A89E9-8312-45A2-8DF4-E140ECAE080B @default.
- Q102215800 P356 BJH.17170 @default.
- Q102215800 P698 33216951 @default.
- Q102215800 P1433 Q4970200 @default.
- Q102215800 P1476 "Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment" @default.
- Q102215800 P2093 "Agnès Veyradier" @default.
- Q102215800 P2093 "Christophe Barba" @default.
- Q102215800 P2093 "Dana Ranta" @default.
- Q102215800 P2093 "Marion Peyre" @default.
- Q102215800 P2093 "Pascal Cathebras" @default.
- Q102215800 P2093 "Paul Coppo" @default.
- Q102215800 P2093 "Sandrine Malot" @default.
- Q102215800 P31 Q13442814 @default.
- Q102215800 P356 "10.1111/BJH.17170" @default.
- Q102215800 P50 Q88547428 @default.
- Q102215800 P577 "2020-11-20T00:00:00Z" @default.
- Q102215800 P698 "33216951" @default.
- Q102215800 P921 Q1426491 @default.
- Q102215800 P921 Q412323 @default.